Scientific program

Thursday, November 23, 2017

14:00 - 14:15 Opening ceremony

Chair: WE Fibbe (The Netherlands)


Tissue specificity of stromal cells

Chair: F Dazzi (United Kingdom)

  • Stromal cells in the hematopoietic niche
    S Mendez Ferrer (United Kingdom)
  • Diversity of stromal cells in the skin
    F Watt (United Kingdom)
  • The role of mesenchymal inflammation in leukemia evolution
    M Raaijmakers (The Netherlands)
15:45 - 16:15 Coffee break

16:15 - 17:30 ABSTRACT SESSION

Biology of MSC

Chair: WE Fibbe (The Netherlands)
  • 1.1. Gene network analysis of the hematopoietic stem/progenitor cell-supportive bone marrow mesenchymal stromal cells
    P Charbord (France)
  • 1.2. The transcriptional landscape of the Aorta-Gonad-Mesonephros hematopoietic microenvironment
    C Durand (France)
  • 1.3. Impairment in the mesenchymal stromal cell niche of Beta-thalassemia patients: implications of prolonged iron exposure
    M Bernardo (Italy)
  • 1.4. Differential RNA expression profile of human bone marrow mesenchymal stromal cells after in vitro expansion in clinical grade human platelet lysate versus fetal calf serum
    A De Becker (Belgium)
  • 1.5. Mesenchymal stromal cells induce a permissive state in the bone marrow that enhances G-CSF-induced mobilization in mice
    M van Pel (The Netherlands)
  • 1.6. Ex vivo fucosylation of adipose mesenchymal stem cells improves their prophylactic efficacy in murine acute graft-versus-host disease
    JE Millán-Rivero (Spain)
  • 1.7. Changes In MSCs characteristics after interaction With lymphocytes do not depend on their compatibility
    NA Petinati (Russia)

17:30 - 18:00 ABSTRACT SESSION

Clinical and Regulatory Aspects

Chair: F Dazzi (United Kingdom)

  • 2.1. Excellent response and low mortality in 69 patients with severe steroid and therapy-refractory agvhd after treatment with mesenchymal stromal cells generated from pooled bone marrow mononuclear cells of multiple donors (MSC-FFM)
    S Kuci (Germany)
  • 2.2. The international phase III MSC trial challenge
    LEM Oosten (The Netherlands)

18:00 - 19:00 Welcome reception


Friday, November 24, 2017


MSC and the tumor microenvironment

Chair: Y Shi (China)

  • Stromal function in the evolving tumor microenvironment: a role in immune modulation?
    J Shields (United Kingdom)
  • Ontogeny and function of tumor-associated macrophages
    T Lawrence (France)
  • Role of myeloid-derived suppressor cells in cancer immune evasion
    V Bronte (Italy)

10:30 - 11:00 Coffee break


Product development

Chair: WE Fibbe (The Netherlands)

  • MSCs and tissue immune microenvironment
    Y Shi (China)
  • Potency assays development
    K Schepers (The Netherlands)
  • Mechanism-based biomarker to predict clinical response
    A Galleu (United Kingdom)

12:30 - 13:30 Lunch


Clinical trials

Chair: K Le Blanc (Sweden)

  • Allogeneic adipose-derived MSC for complex perianal fistulas in Crohn’s disease 
    D Garcia-Olmo (Spain)
  • Mesenchymal stromal cells in kidney transplantation: Lessons learned from initial trials
    AJ Rabelink (The Netherlands)
  • Mesenchymal stromal cells for Graft-versus-Host Disease
    M Bornhäuser (Germany)
  • Mesenchymal stromal cells in therapeutic perspective
    WE Fibbe (The Netherlands)

15:30 - 16:00 Coffee break

16:00 - 17:00 ABSTRACT SESSION

Biology and mechanisms of action

Chair: AJ Rabelink (The Netherlands)

  • 3.1. Immunomodulation induced by Mesenchymal stem cells (MSC) is triggered through phagocytosis of MSC by innate immune cells
    SFH de Witte (The Netherlands)
  • 3.2. High-throughput, non-perturbing quantification of mesenchymal stroll cell adipocytic differentiation using Digital Holographic Microscopy
    O Naveiras (Switzerland)
  • 3.3. Membrane particles generated from mesenchymal stromal cells modulate immune responses by selective targeting of pro-inflammatory monocytes
    A Merino (The Netherlands)
  • 3.4. Mesenchymal stem cell genetically engineered to express alpha-1 anti-trypsin show superior efficacy in humanized graft-vs-host-disease model in comparison to native mesenchymal stem cells
    FGH Hermann (Germany)
  • 3.5. The phenotype and role of bone marrow mesenchymal stem and progenitor cells in chronic myeloid leukemia
    M Dolinska (Sweden)
  • 3.6. Low-dose irradiation of mesenchymal stromal cell alters they Adipogenic/Osteogenic differentiation capacity improving their hematopoietic-supporting ability
    S Preciado (Spain)


Towards MSC as a standard of care, where do we stand?

Chair: AJ Rabelink (The Netherlands)


  • FPL Luyten (Belgium)
  • K Le Blanc (Sweden)
  • F Sánchez-Guijo (Spain)

Saturday, November 25, 2017


Clinical issues

Chair: D Niederwieser (Germany)

  • Advanced Therapy Medicinal Products (ATMP) - a rapidly evolving regulatory landscape
    P Hurley (United Kingdom)
  • Ethical considerations in randomized clinical trials with MSC
    K Hug (Sweden)
  • Cell based therapies: Academic or commercial?
    FPL Luyten (Belgium)

10:30 - 11:00 Coffee break


Regulatory and ethical hurdles in clinical trials using MSC, how can they be solved?

Chair: D Niederwieser (Germany)


  • K Hug (Sweden)
  • P Hurley (United Kingdom)
  • Panelist to be announced

11:45 - 13:00 ABSTRACT SESSION

Clinical and translation aspects of MSC

Chair: D Niederwieser (Germany)

  • 4.1. A single-step expansion system for large-fold expansion of bone marrow-derived MSCs
    RHJ Das (The Netherlands)
  • 4.2. Efficiency and safety of application of the conditioning medium of mesenchymal stem cells in chronic anal fissures
    II Gribanov (Russia)
  • 4.3. Placenta-derived mesenchymal stem cells for treatment of steroid-refractory severe gastro-intestinal form of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: Case report
    T Bukreieva (Ukraine)
  • 4.4. High-throughput immunophenotypic characterization of bone marrow- and cord blood-derived mesenchymal stromal cells (MSC) reveals common and differentially expressed markers. Angiotensin-converting enzyme(CD143) is differentially expressed on MSC derived f
    F Elice (Italy)
  • 4.5. Retainment, survival and localization of MSC delivered to porcine kidneys
    JM Sierra Parraga (The Netherlands)
  • 4.6. Clinical trial of intravenous infusion of fucosylated bone marrow mesenchymal stem cells in patients with osteoporosis
    JE Millán-Rivero (Spain)
  • 4.7. Tracking of bone marrow-derived mesenchymal stem cell with Qdot® nano-crystals in an acute hepatic injury experimental model
    ES Seria (Malta)

13:00 - 13:15 Closing ceremony

Chair: F Dazzi (United Kingdom)

13:15 - 14:00 Lunch